LUMIFY Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Lumify, and when can generic versions of Lumify launch?

Lumify is a drug marketed by Bausch And Lomb Inc and is included in two NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in sixteen countries.

The generic ingredient in LUMIFY is brimonidine tartrate. There are eleven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lumify

A generic version of LUMIFY was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28^th, 2003.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for LUMIFY?
What are the global sales for LUMIFY?
What is Average Wholesale Price for LUMIFY?

Summary for LUMIFY

International Patents:	37
US Patents:	4
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	6
Patent Applications:	330
Drug Prices:	Drug price information for LUMIFY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUMIFY
DailyMed Link:	LUMIFY at DailyMed

Drug patent expirations by year for LUMIFY

Recent Clinical Trials for LUMIFY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tulane University	Phase 4
University of Louisville	Phase 4
Bausch & Lomb Incorporated	Phase 3

See all LUMIFY clinical trials

Pharmacology for LUMIFY

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

Paragraph IV (Patent) Challenges for LUMIFY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUMIFY	Ophthalmic Solution	brimonidine tartrate	0.025%	208144	1	2021-07-12

US Patents and Regulatory Information for LUMIFY

LUMIFY is protected by four US patents.

Patents protecting LUMIFY

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS

Preferential vasoconstriction compositions and methods of use
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS

Compositions and methods for eye whitening
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Bausch And Lomb Inc	LUMIFY PRESERVATIVE FREE	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	218424-001	Apr 19, 2024		OTC	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Bausch And Lomb Inc	LUMIFY PRESERVATIVE FREE	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	218424-001	Apr 19, 2024		OTC	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for LUMIFY

See the table below for patents covering LUMIFY around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
European Patent Office	2696874	COMPOSITIONS ET MÉTHODES UTILISÉES DE TRAITEMENT D'AFFECTIONS NASALES (COMPOSITIONS AND METHODS FOR THE TREATMENT OF NASAL CONDITIONS)	⤷ Sign Up
Russian Federation	2016111112	КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ЛЕЧЕНИЯ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ НОСА	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2010014552		⤷ Sign Up
Japan	2013514985		⤷ Sign Up
Denmark	2320911		⤷ Sign Up
Japan	5671459		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for LUMIFY

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	92462	Luxembourg	⤷ Sign Up	PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225
1631293	2014C/042	Belgium	⤷ Sign Up	PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221
1631293	2014/041	Ireland	⤷ Sign Up	PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293	C300683	Netherlands	⤷ Sign Up	PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	14C0056	France	⤷ Sign Up	PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	300683	Netherlands	⤷ Sign Up	PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description